The Integrated Forecasting and Analysis Tool   Login Now

Allergan

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Allergan are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Allergan, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Allergan 1 Botox onaclostox Acetylcholine release inhibitor 982 1,212   23%     2 Lumigan bimatoprost Prostaglandin F2 analogue 328 392   20%     3 Restasis cyclosporin Tear secretion enhancer 270 345   27%       Note: Shaded Cells

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Allergan 1 Posurdex Sensory Organs Eye preparations Corticosteroid Phase III   2 Trivaris Sensory Organs Eye preparations Corticosteroid Phase III   - Androgen Tears Sensory Organs Eye preparations Eye preparation Phase II

DEALS - Selected Company Deals

Rank Deal Date Deal Type Product Status on Deal Date Deal Partner/ Product Source Deal Value Allergan 1 Aug 2007 In-licensed Sanctura XR Approved Indevus Pharmaceuticals 50

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Allergan   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 17,364 17,364        PE Ratio (diluted) - Normalised (x) 33.2 30.6        Valuing the Enterprise        Enterprise Value 17,836 17,836        Free Cash Flow (Pre-Dividends) 249 630        FCF Yield (%) 1.4% 3.5%    Forecast Financials   Income Statement      Total Revenues 2,343 3,063      Cost of Goods Sold (385) (527)      S,G & A (947) (1,280)      R&D (384) (476)      Other Income/ Expense - Net (28) (23)      EBIT - Normalised 599 758      Net Interest & Financial Items 25 (11)      Pre-tax Profits - Normalised 624 747      Exceptionals (25) (767)      Income Before Taxes 599 (20)      Tax (192) (108)      Tax Rate (%) 32.1% 551.3%      Minorities 0 0      Extraordinary (3) -      Net Income - Reported 404 (127)      Net Income - Normalised 460 547     Per Share Data      EPS - Diluted 1.51 (0.43)      EPS - Basic 1.54 (0.43)      EPS - Normalised (diluted) 1.71 1.86      EPS - Normalised (basic) 1.75 1.86      Avg. Shares Outstanding - Diluted 268.0 293.8      Avg. Shares Outstanding - Basic 262.2 293.8      DPS 0.20 0.20

NEWS - Selected Product News Headlines (as of 11 June 2008)

Allergan Announces Intent to File New Drug Application for Bimatoprost as Novel Treatment to Stimulate Natural Eyelash Growth   (Allergan)   04-Jun-2008 Allergan batting its lashes at success with Lumigan spin off?   (Allergan)   04-Jun-2008 Akorn, Inc. Announces FDA Approval of Ofloxacin Ophthalmic Solution USP, 0.3%   (Akorn)   16-Apr-2008 Allergan, Inc. Receives FDA Approval for COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%   (Allergan)   31-Oct-2007 Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb   (Novavax)   25-Oct-2007 Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials   (ExonHit Therapeutics)   28-Aug-2007 Indevus Announces FDA Approval of SANCTURA(R) XR   (Indevus Pharmaceuticals)   06-Aug-2007 ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate   (ACADIA Pharmaceuticals)   16-Jul-2007 Allergan Announces FDA Approval of Label Extensions for JUVEDERM(TM) Ultra and JUVEDERM(TM) Ultra Plus   (Allergan)   26-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Allergan AC-262271 -   Acular ketorolac tromethamine   AGN 194310 -   AGN 195795 -   AGN 197075 -   AGN 199981 -   AGN 201781 -   AGN 203818 -   AGN211745 -   AGN-XX -   AGN-YY -   Alocril nedocromil sodium   Alphagan brimonidine tartrate   Amerge naratriptan   Androgen Tears -   Androsorb testosterone   Aphrodyne yohimbine   ATX-S10 -   Azelex azelaic acid   Betagan levobunolol   BioLon sodium hyaluronate   Blephamide Line prednisolone & sulfacetamide   Botox onaclostox   Captique sodium hyaluronate   Celluvisc carboxymethylcellulose sodium   Chloroptic chloramphenicol   Combigan brimonidine & timolol maleate   Contigen collagen   CosmoDerm collagen   CosmoPlast collagen   EHT/AGN 001 -   EHT/AGN 002 -   Elestat/Relestat epinastine   Elimite permethrin   Erymax erythromycin   Estrasorb 17-beta estradiol   Eye Care Research Project -   Finacea azelaic acid   Fluoroplex fluorouracil   FML Line fluorometholone   Ganfort bimatoprost & timolol   Gris-Peg griseofulvin   Herbe benzalkonium chloride   Hylaform sodium hyaluronate   Imidazyl naphazoline   Imitrex sumatriptan   I-PREX rBPI-21   Juvéderm/Hydrafill -   Lacri-Lube paraffin (liquid)   Lerin -   Liquifilm polyvinyl alcohol   Lumigan bimatoprost   M.D.Forte acetohydroxamic acid   Memantine memantine   MyoBloc botulinum toxin type B   Na+ Channel Blockers -   Naftin naftifine   Ocufen flurbiprofen   Ocuflox ofloxacin   Ophthalmic RNAi Research Project -   Opticrom cromolyn sodium   Optive carboxymethylcellulose sodium   Panzem 2-methoxyestradiol   Peplin (PEP005) ingenol   Photoplex avobenzone & padimate O   Polytrim trimethoprim & polymyxin   Posurdex dexamethasone   Pred Forte prednisolone   Prevage idebenone   Prolacria diquafosol tetrasodium   Pro-Omeprazole -   Propine dipivefrin   Prosed EC atropine, benzoic acid, hyoscyamine, methenamine, methylene blue & phenyl salicylate   Prosed/DS atropine, benzoic acid, hyoscyamine, methenamine, methylene blue & phenyl salicylate   PS388023 -   Refresh carboxymethylcellulose sodium   Restasis cyclosporin   Sanctura trospium chloride   Sanctura XR trospium chloride   Tazorac/Zorac tazarotene   Trivaris triamcinolone acetonide   Tyrosine Kinase Inhibitors -   Uro-KP Neutral orthophosphate   Urolene Blue methylene blue   Virilon methyltestosterone   Vitrase hyaluronidase (ovine)   Xeomin botulinum toxin type A   Zyderm collagen   Zymar gatifloxacin   Zyplast collagen

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:53:32 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd